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THE RESULTS of kidney transplantation in African-Americans have improved with oetter immunosup-
pressive regimens. but the overall graft survival is reported 
by many to be inferior to that of non-Black recipients. 1- 3 
The underlying impact of such factors as HLA matching. 
immunosuppressive regimes. socioeconomic status. or cen-
ter effect has remained in question as many examine the 
underlying cause for the poorer graft survival.2.4 
Our early experience with the use of tacrolimus has 
shown no difference in kidney allograft survival when 
compared to thc non-Black recipients.' 
We examine the outcome of the use of tacrolimus. a 
better immunosuppressive agent. to evaluate the effect of 
graft survival in African-American patients undergoing 
renal transplantation alone at the University of Pittsburgh. 
Minimum follow-up is 12 months. 
PATIENTS AND METHODS 
From October 1989 to December 1995. 1204 patients undelWent 
kidney transplants at the University of Pittsburgh. One hundred 
fifty four were performed in 148-African Americans (13%). Ex-
cluded from the analysis were 16 patients who received a kidney in 
combination with bone marrow. liver. pancreas. or islet-cell trans-
plantation. Of the remaining 138 transplants. 86 (62%) were 
treated with tacrolimus and steroids alone. Triple-therapy using 
azathioprine was the regimen in 31 (22%). cyclophosphamide in 16 
(12%). and mycophenolate mofetil in 5 (4%). 
Adults made up 96% of patients with a mean age of 43 :': 13 
years. One hundred four (76%) patients received their first trans-
plant. while 32 patients undelWent retransplantation (25 second 
grafts. 6 third grafts. and 1 fourth graft.) The most common 
etiologies of renal failure were hypertension and diabetes. Panel 
reactive antibody level was 40 or less in 87% of the transplants. 
Cadaveric donors accounted for 92% of the transplants. 
RESULTS 
The 1- and 3-year actuarial patient survival was 96% and 
92%. respectively (Fig 1). The 1- and 3-year actuarial graft 
survival was 86% and 70%. respectively. Twenry of 52 failed 
grafts were lost in the first year after transplantation. 11 as 
the result of nonfunction and/or rejection. 
Rejection was seen in 6R'.0 of the transplants. Twenty-five 
(1St;(,) required OKT3 for steroid-resistant rejection. Fif-
teen of these went on to graft failure: six within the first vear 
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Fig 1. African-American kidney transplantation under tacroli-
mus: patient and graft survival. 
after transplantation. Loss of graft in all 15 cases was 
associated with infection and/or rejection. There were IS 
deaths: eight while on dialysis and 10 with a functioning 
graft. New onset diabetes was seen in 28 (25.7%) patients at 
risk, of whom 13 were able to discontinue insulin after 
lowering immunosuppression. Only 2% of the transplants 
were associated with a six HLA antigen-matched kidney. 
Eighty-four percent received a one to three antigen-
matched graft. 
The mean creatinine at 1 and 3 years was 1.9 + 1.0 mgldL 
and 3.3 + 3.3 mgldL. respectively. The mean tacrolimus 
dose was 17 + 10 mgldL per day at I year and 13 + 7.0 
mgldL per day at 3 years. 
DISCUSSION 
The overall graft survival for kidney transplantation has 
improved progressively, with better immunosuppressive 
regimens both for Black and non-Black recipients. Despite 
earlier reports of poorer kidney allograft survival in Afri-
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can-Americans." 7 many others havc reported no racial 
differences in the outcome of renal transplantation. -.S How-
ever. sueh reports have tended to have relatively short 
follow-up periods. In our analysis of ~ III African-Ameri-
cans among the P1KO~l pnmary cadaveric kidncv reCipients 
in the 1991-1995 UNOS Scientitic Reglstrv Study." the 
I-year graft survival was essentially the same as the 23.280 
"all other." Between I and 3 vears. however. the Afriean-
Americans lost about 10% more grafts than the "all others" 
at every level of HLA match. 
Since beginning the use of tacrolimlls at the University of 
Pittsburgh in 1989. kidney transplant recipients have re-
ceived tacrolimus as part of a randomized double or triple 
drug regimen. Induction antilymphocytic globulin has not 
been used routinely. Our results of patient and graft 
survival in this subgroup group of African-Americans arc 
equivalent to those found in an earlier smaller series 
reported by Shapiro et al 10 and are similar to those of 
others using quadruple therapy with OKT3 induction.ll.l; 
The fiscal and quality of life advantages of using tacrolimus 
without OKT3 are obvious. 
While many factors are responsible for the poorer out-
come of African-Americans undergoing kidney transplan-
tation, improved immunosuppression is more likely to play 
a significant role in the long-term than other proposed 
mechanisms. The challenge of improving the long-term 
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graft sUl>wal in the African-American population will 
depend partly 'lll the abilitv to control rejection at noth the 
earlv and late stages after transplantatIOn. 
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